SCH-58500 + chemotherapy

SCH-58500 + chemotherapy is a **combination therapy** consisting of **SCH-58500**, a recombinant, replication-deficient adenoviral vector expressing the human wild-type p53 tumor suppressor gene, administered together with standard **chemotherapy agents** (notably platinum-based agents such as carboplatin and paclitaxel)[3][5]. SCH-58500 functions as a gene therapy: by introducing wild-type p53 into cancer cells harboring mutant or absent p53, it aims to restore tumor suppressor function, induce cell-cycle arrest, and promote apoptosis. This regimen has been in clinical trials for solid tumors, especially recurrent ovarian, primary peritoneal, and fallopian tube cancers with mutant/aberrant p53[2][3]. Combination use is based on hypothesized synergy, as chemotherapy can induce p53-independent apoptosis, potentially enhancing tumor cell death when combined with p53 restoration[3][5].

Other names

rAd/p53recombinant adenoviral p53 gene therapy (in context)adenoviral vector encoding wild-type p53 + chemotherapy